Hopes fad­ing, Onco­Genex ac­knowl­edges a PhI­II flop for can­cer drug

Any dwin­dling hopes that in­vestors still had in Onco­Genex $OGXI large­ly evap­o­rat­ed Tues­day morn­ing when the Seat­tle-based biotech re­port­ed that its late-stage ef­fort for cu­stirsen failed a Phase III study for cas­tra­tion re­sis­tant prostate can­cer.

The Phase III fail­ure is spurring Onco­Genex to see if it can get a green light from the FDA to get an ear­ly look at a sep­a­rate study for non-small cell lung can­cer as it as­sess­es its re­main­ing prospects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER